Interestingly, the effect of selumetinib on Arg1 expression in the tumor is associated with the down-regulation of Cox-2 (Fig. 5a-c) on day 8, but not on day 1 when only Cox-2 is reduced compared to control. The gene discussed is ARG1; the disease is neoplasm.